XML 52 R39.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Significant Agreements - Summary of Agreement (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 5 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | ---
Jul. 31, 2018 USD ($) | May 31, 2018 USD ($) item | Jul. 31, 2017 USD ($) | Mar. 31, 2017 USD ($) item | May 31, 2016 USD ($) | May 31, 2015 USD ($) item | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Sep. 30, 2017 USD ($) | Sep. 30, 2018 USD ($) | Sep. 30, 2018 USD ($) item | Sep. 30, 2017 USD ($) | Dec. 31, 2017 USD ($)
Collaboration and other research and development revenues |  |  |  |  |  |  | $ 14,519 |  |  |  | $ 25,818 |  |
Revenue type |  |  |  |  |  |  | us-gaap:ServiceMember |  |  |  | us-gaap:ServiceMember |  |
Research and development |  |  |  |  |  |  | $ 17,443 |  | $ 20,396 |  | $ 71,460 | $ 56,735 |
Deferred revenue |  |  |  |  |  |  | 112,825 |  |  | $ 112,825 | 112,825 |  | $ 107,963
Deferred revenue, long-term |  |  |  |  |  |  | 104,100 |  |  | 104,100 | 104,100 |  | 94,725
Accounts receivable |  |  |  |  |  |  | 43 |  |  | 43 | 43 |  | 679
Juno Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |
Allocable arrangement consideration - R&D Services Unit of Accounting |  |  |  |  |  |  | 15,800 |  |  | 15,800 | 15,800 |  |
Allocable arrangement consideration - Development and Commercialization License for the first research area |  |  |  |  |  |  | 3,600 |  |  | 3,600 | 3,600 |  |
Allocable arrangement consideration - Development and Commercialization License for the second research area |  |  |  |  |  |  | 6,000 |  |  | 6,000 | 6,000 |  |
Allocable arrangement consideration - Development and Commercialization License for the third research area |  |  |  |  |  |  | 100 |  |  | 100 | 100 |  |
Allocable arrangement consideration - Development and Commercialization License for the fourth research area |  |  |  |  |  |  | 18,300 |  |  | 18,300 | 18,300 |  |
Allocable arrangement consideration - First additional Development and Commercialization License for the first research area |  |  |  |  |  |  | 300 |  |  | 300 | 300 |  |
Allocable arrangement consideration - Second additional Development and commercialization license for the first research area |  |  |  |  |  |  | 200 |  |  | 200 | 200 |  |
Allocable arrangement consideration - Third additional Development and commercialization license for the first research area |  |  |  |  |  |  | 100 |  |  | 100 | 100 |  |
Allocable arrangement consideration - First additional Development and commercialization license for the second research area |  |  |  |  |  |  | 800 |  |  | 800 | 800 |  |
Allocable arrangement consideration - Second additional Development and commercialization license for the second research area |  |  |  |  |  |  | 500 |  |  | 500 | 500 |  |
Allocable arrangement consideration - Third additional Development and commercialization license for the second research area |  |  |  |  |  |  | 300 |  |  | 300 | 300 |  |
Collaboration and other research and development revenues |  |  |  |  |  |  | $ 700 |  | $ 3,100 |  | $ 5,200 | $ 4,400 |
Revenue type |  |  |  |  |  |  | us-gaap:ServiceMember |  | us-gaap:ServiceMember |  | us-gaap:ServiceMember | us-gaap:ServiceMember |
Revenue recognized related to milestone payment |  |  |  |  |  |  |  |  | $ 2,500 |  |  | $ 2,500 |
Additional revenue related to cumulative catch-up adjustments |  |  |  |  |  |  |  |  |  |  | $ 3,000 |  |
Deferred revenue |  |  |  |  |  |  | $ 33,200 |  |  | 33,200 | 33,200 |  | 26,400
Deferred revenue, long-term |  |  |  |  |  |  | 32,600 |  |  | 32,600 | 32,600 |  | 26,400
Accounts receivable |  |  |  |  |  |  | 0 |  |  | 0 | $ 0 |  | 500
Allergan |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional licenses | item |  |  |  |  |  |  |  |  |  |  | 2 |  |
Potential development milestone payments |  |  |  |  |  |  | 8,000 |  |  | 8,000 | $ 8,000 |  |
One time payment to acquire the license |  |  |  |  |  |  | 25,000 |  |  | 25,000 | $ 25,000 |  |
Number of days in which payment to be made |  |  |  |  |  |  |  |  |  |  | 45 days |  |
Allergan | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development milestone payments |  |  |  |  |  |  | 42,000 |  |  | 42,000 | $ 42,000 |  |
Potential regulatory and commercial milestone payments |  |  |  |  |  |  | 75,000 |  |  | 75,000 | 75,000 |  |
Potential commercial milestone payments |  |  |  |  |  |  | 90,000 |  |  | 90,000 | 90,000 |  |
Collaboration and License Agreement | Juno Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |
Number of research areas | item |  |  |  |  |  | 3 |  |  |  |  |  |  |
Agreement term |  |  |  |  |  | 5 years |  |  |  |  |  |  |
Extensions | item |  |  |  |  |  | 2 |  |  |  |  |  |  |
Extension period |  |  |  |  |  | 1 year |  |  |  |  |  |  |
Upfront fee received |  |  |  |  |  | $ 25,000 |  |  |  |  |  |  |
Potential research and development funding |  |  |  |  |  | $ 22,000 |  |  |  |  |  |  |
Number of additional licenses | item |  |  |  |  |  | 3 |  |  |  |  |  |  |
Potential fee receivable for each gene target licensed |  |  |  |  |  | $ 2,500 |  |  |  |  |  |  |
Potential development milestone payments |  |  |  |  |  | 77,500 |  |  |  |  |  |  |
Potential regulatory milestone payments |  |  |  |  |  | 80,000 |  |  |  |  |  |  |
Potential commercial milestone payments |  |  |  |  |  | $ 75,000 |  |  |  |  |  |  |
Milestone payment received under license agreement |  |  | $ 2,500 |  | $ 2,500 |  |  |  |  |  |  |  |
Collaboration and License Agreement | Allergan |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  | 2,800 |  |  |  | 2,800 |  |
Research and development expense |  |  |  |  |  |  | 1,100 |  |  |  | 1,100 |  |
Amended Collaboration and License Agreement | Juno Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |
Number of research areas | item |  | 4 |  |  |  |  |  |  |  |  |  |  |
Additional upfront fee received |  | $ 5,000 |  |  |  |  |  |  |  |  |  |  |
Number of milestones related to technical progress | item |  | 2 |  |  |  |  |  |  |  |  |  |  |
Milestone payment receivable related to technical progress |  | $ 2,500 |  |  |  |  |  |  |  |  |  |  |
Potential development milestone payments |  | 80,000 |  |  |  |  |  |  |  |  |  |  |
Potential regulatory milestone payments |  | $ 80,000 |  |  |  |  |  |  |  |  |  |  |
Number of milestone payment received | item |  | 2 |  |  |  |  |  |  |  |  |  |  |
Milestone payment received under license agreement |  | $ 2,500 |  |  |  |  |  |  |  |  |  |  |
Next possible milestone payment |  |  |  |  |  |  | 2,500 |  |  | 2,500 | 2,500 |  |
Collaboration and other research and development revenues |  |  |  |  |  |  |  |  |  | 0 |  |  |
Additional revenue related to cumulative catch-up adjustments |  |  |  |  |  |  |  |  |  | 0 |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  | 1,700 |  |
Strategic Alliance | Allergan |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement term |  |  |  | 7 years |  |  |  |  |  |  |  |  |
Extension period |  |  |  | 1 year |  |  |  |  |  |  |  |  |
Upfront fee received |  |  |  | $ 90,000 |  |  |  |  |  |  |  |  |
Number of Collaboration Development Programs | item |  |  |  | 5 |  |  |  |  |  |  |  |  |
Number of Committee Members | item |  |  |  | 3 |  |  |  |  |  |  |  |  |
Option exercise price per CDP |  |  |  | $ 15,000 |  |  |  |  |  |  |  |  |
Extension fee for Initial Option Period |  |  |  | 5,000 |  |  |  |  |  |  |  |  |
Option exercise price for development and commercialization license |  |  |  | $ 22,500 |  |  |  |  |  |  |  |  |
Collaboration and other research and development revenues |  |  |  |  |  |  | $ 13,800 |  | $ 3,200 |  | $ 16,700 | $ 5,600 |
Revenue type |  |  |  |  |  |  | us-gaap:ServiceMember |  | us-gaap:ServiceMember |  | us-gaap:ServiceMember | us-gaap:ServiceMember |
Deferred revenue |  |  |  |  |  |  | $ 79,100 |  |  | 79,100 | $ 79,100 |  | 81,200
Deferred revenue, long-term |  |  |  |  |  |  | 71,500 |  |  | 71,500 | $ 71,500 |  | $ 68,300
Contract termination notice |  |  |  |  |  |  |  |  |  |  | 90 days |  |
Option exercise payment received | $ 15,000 |  |  |  |  |  |  |  |  |  |  |  |
Strategic Alliance | Allergan | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Extension period |  |  |  | 10 years |  |  |  |  |  |  |  |  |
Sponsored Research Agreement | Broad |  |  |  |  |  |  |  |  |  |  |  |  |
First research funding amount due and payable |  |  |  |  |  |  | 5,000 |  |  | 5,000 | $ 5,000 |  |
Second research funding amount due and payable |  |  |  |  |  |  | 7,500 |  |  | 7,500 | 7,500 |  |
Research and development |  |  |  |  |  |  |  | $ 12,500 |  |  |  |  |
Sponsored Research Agreement | Broad | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Research funding amount due and payable |  |  |  |  |  |  | 125,000 |  |  | $ 125,000 | 125,000 |  |
License Agreement | Allergan |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  | 2,300 |  | $ 6,700 |  | 2,300 | $ 14,100 |
License Agreement | Beam Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and other research and development revenues |  |  |  |  |  |  | $ 100 |  |  |  | $ 4,000 |  |
Revenue type |  |  |  |  |  |  |  |  |  |  | us-gaap:ServiceMember |  |
Non-cash consideration aggregate fair value received |  | $ 3,600 |  |  |  |  |  |  |  |  |  |  |
Contract termination notice |  | 90 days |  |  |  |  |  |  |  |  |  |  |

X
- Definition Additional cash received from collaborators during the current + References No definition available. + Details
Name: | edit_AdditionalProceedsFromCollaborators
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the additional revenue related to cumulative catch-up adjustments. + References No definition available. + Details
Name: | edit_AdditionalRevenueRelatedToCumulativeCatchUpAdjustment
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of extensions to the agreement permitted under the agreement. + References No definition available. + Details
Name: | edit_AgreementExtensionNumber
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of extensions to the agreement permitted under the agreement. + References No definition available. + Details
Name: | edit_AgreementExtensionPeriod
Namespace Prefix: | edit_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of potential future consideration under the arrangement allocated to the Development and Commercialization License for the first research area at the inception of the agreement. + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationDevelopmentAndCommercializationLicenseResearchArea1
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The portion of potential future consideration under the arrangement allocated to the Development and Commercialization License for the second research area + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationDevelopmentAndCommercializationLicenseResearchArea2
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The portion of potential future consideration under the arrangement allocated to the Development and Commercialization License for the third research area at the inception of the agreement. + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationDevelopmentAndCommercializationLicenseResearchArea3
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The portion of potential future consideration under the arrangement allocated to the Development and Commercialization License for the fourth research area at the inception of the agreement. + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationDevelopmentAndCommercializationLicenseResearchArea4
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The portion of potential future consideration under the arrangement allocated to the first additional Development and Commercialization License for the first research area at the inception of the agreement. + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationFirstAdditionalDevelopmentAndCommercializationLicenseResearchArea1
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The portion of potential future consideration under the arrangement allocated to the first additional Development and Commercialization License for the second research area at the inception of the agreement. + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationFirstAdditionalDevelopmentAndCommercializationLicenseResearchArea2
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The portion of potential future consideration under the arrangement allocated to the R&D Services Unit of Accounting at the inception of the agreement. + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationResearchAndDevelopmentServicesUnitOfAccounting
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The portion of potential future consideration under the arrangement allocated to the second additional Development and Commercialization License for the first research area at the inception of the agreement. + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationSecondAdditionalDevelopmentAndCommercializationLicenseResearchArea1
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The portion of potential future consideration under the arrangement allocated to the second additional Development and Commercialization License for the second research area at the inception of the agreement. + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationSecondAdditionalDevelopmentAndCommercializationLicenseResearchArea2
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The portion of potential future consideration under the arrangement allocated to the third additional Development and Commercialization License for the first research area at the inception of the agreement. + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationThirdAdditionalDevelopmentAndCommercializationLicenseResearchArea1
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The portion of potential future consideration under the arrangement allocated to the third additional Development and Commercialization License for the second research area at the inception of the agreement. + References No definition available. + Details
Name: | edit_AllocableArrangementConsiderationThirdAdditionalDevelopmentAndCommercializationLicenseResearchArea2
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of the next potential milestone payment which the reporting entity could receive. + References No definition available. + Details
Name: | edit_AmountNextMilestonePotentialPayment
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the Initial Option Period extension fee under the strategic alliance and option agreement. + References No definition available. + Details
Name: | edit_CollaborationDevelopmentProgramInitialOptionPeriodExtensionFeeUnderStrategicAllianceAndOptionAgreement
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the option exercise price for development and commercialization license after the Initial option period under the strategic alliance and option agreement. + References No definition available. + Details
Name: | edit_CollaborationDevelopmentProgramOptionExerciseFeeForDevelopmentAndCommercializationUnderStrategicAllianceAndOptionAgreement
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the option exercise price during the Initial option period for each collaboration development program under the strategic alliance and option agreement. + References No definition available. + Details
Name: | edit_CollaborationDevelopmentProgramOptionExerciseFeeUnderStrategicAllianceAndOptionAgreement
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The research funding amount due and payable. + References No definition available. + Details
Name: | edit_FundingPaymentsDueAndPayable
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The first research funding amount which is due and payable. + References No definition available. + Details
Name: | edit_FundingPaymentsDueAndPayableOne
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The first research funding amount due and payable + References No definition available. + Details
Name: | edit_FundingPaymentsDueAndPayableTwo
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the contract termination notice term under the license agreement. + References No definition available. + Details
Name: | edit_LicenseAgreementContractTerminationTerm
Namespace Prefix: | edit_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the milestone payment received under the license agreement. + References No definition available. + Details
Name: | edit_LicenseAgreementMilestonePaymentReceived
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payment receivable related to technical progress in research area. + References No definition available. + Details
Name: | edit_MilestonePaymentReceivableRelatedToTechnicalProgressInResearchArea
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate fair value of non-cash consideration received under the agreement. + References No definition available. + Details
Name: | edit_NonCashConsiderationReceivedAggregateFairValue
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of additional development and Commercialization License that can be purchased. + References No definition available. + Details
Name: | edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of collaboration development programs for the treatment of ocular disorders under the exclusive license from the company. + References No definition available. + Details
Name: | edit_NumberOfCollaborationDevelopmentPrograms
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of members in the alliance steering committee (ASC) that was formed under the Allergan Agreement. + References No definition available. + Details
Name: | edit_NumberOfCommitteeMembers
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of milestone payment received under the license agreement. + References No definition available. + Details
Name: | edit_NumberOfMilestonePaymentReceived
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of milestones related to technical progress. + References No definition available. + Details
Name: | edit_NumberOfMilestonesRelatedToTechnicalProgress
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of research areas defined in the agreement. + References No definition available. + Details
Name: | edit_NumberOfResearchAreas
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of one time payment to acquire the license. + References No definition available. + Details
Name: | edit_OneTimePaymentToAcquireLicense
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the amount of option exercise payment received. + References No definition available. + Details
Name: | edit_OptionExercisePaymentReceived
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount which the collaborator will pay to the reporting entity for research and development over the term of the agreement. + References No definition available. + Details
Name: | edit_PotentialCashPaymentsForResearchAndDevelopmentFunding
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The potential fees which the reporting entity could receive for achievement of regulatory milestones. + References No definition available. + Details
Name: | edit_PotentialCommercialMilestonePayments
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The potential fees which the reporting entity could receive for achievement of regulatory milestones. + References No definition available. + Details
Name: | edit_PotentialDevelopmentMilestonePayments
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The potential fee which the reporting entity could receive from the collaborator for each gene target identified under the Development and Commercialization License + References No definition available. + Details
Name: | edit_PotentialFeeReceivableForGeneTargetsUnderDevelopmentAndCommercializationLicense
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The potential fees which the reporting entity could receive for achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | edit_PotentialRegulatoryAndCommercialMilestonePayments
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The potential fees which the reporting entity could receive for achievement of regulatory milestones. + References No definition available. + Details
Name: | edit_PotentialRegulatoryMilestonePayments
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the amount of reimbursable research and development expense. + References No definition available. + Details
Name: | edit_ReimbursableResearchAndDevelopmentExpense
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The term of the research program under the agreement. + References No definition available. + Details
Name: | edit_ResearchProgramTerm
Namespace Prefix: | edit_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of revenue recognized related to milestone payment. + References No definition available. + Details
Name: | edit_RevenueRelatedToMilestonePaymentRecognized
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of days in which the payment is to be made by the company on acceptance by the applicable regulatory authority of the Company’s submission of an IND application with respect to the LCA10 Program. + References No definition available. + Details
Name: | edit_ThresholdNumberOfDaysInWhichPaymentToBeMadeOnAcceptanceOfApplication
Namespace Prefix: | edit_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-06(3)) -URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_ReceivablesNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Indicates type of revenue from product and service. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 55 -Paragraph 91 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046 + Details
Name: | us-gaap_TypeOfRevenueExtensibleList
Namespace Prefix: | us-gaap_
Data Type: | srt-types:extensibleListItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=edit_JunoTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=edit_AllerganMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_AmendedAndRestatedCollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_StrategicAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_SponsoredResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=edit_BroadInstituteIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=edit_BeamTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |